Latest Amgen Stories
THOUSAND OAKS, Calif., Oct. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the fourth quarter of 2014.
Amgen Seeks Injunction Related to PCSK9 Inhibitor THOUSAND OAKS, Calif., Oct.
Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options THOUSAND OAKS,
Primary Efficacy Analysis Demonstrates Clinical Equivalence THOUSAND OAKS, Calif., Oct.
CRANBURY, N.J., Oct.
Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia
Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio THOUSAND OAKS, Calif., Oct.
THOUSAND OAKS, Calif., Sept. 24, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc.
- an ornament or knob in the shape of a flower
- In architecture, a floral ornament; specifically, the large conventional flower usually placed in the center of the abacus of a Corinthian capital or classic ceiling-caisson; also, the floreated termination of a Gothic finial.